Additional file 4: of Patients with metastatic renal cell carcinoma who benefit from axitinib dose titration: analysis from a randomised, double-blind phase II study

Tomita, Yoshihiko; Uemura, Hirotsugu; Oya, Mototsugu; Shinohara, Nobuo; Habuchi, Tomonori; Fujii, Yosuke; Kamei, Yoichi; Umeyama, Yoshiko; Bair, Angel; Rini, Brian

doi:10.6084/m9.figshare.7559405.v1

12885_2018_5224_MOESM4_ESM.pdf (73.57 kB)

Additional file 4: of Patients with metastatic renal cell carcinoma who benefit from axitinib dose titration: analysis from a randomised, double-blind phase II study

journal contribution

posted on 2019-01-07, 05:00 authored by Yoshihiko Tomita, Hirotsugu Uemura, Mototsugu Oya, Nobuo Shinohara, Tomonori Habuchi, Yosuke Fujii, Yoichi Kamei, Yoshiko Umeyama, Angel Bair, Brian Rini

Table presenting âCommon, all-causality adverse events reported in patients with OS âĽ24 versus <24 months in the placebo titration arm.â (PDF 73 kb)

Funding

Pfizer

History

Usage metrics

Keywords

Axitinib Benefit with dose titration First-line Metastatic renal cell carcinoma Predictive factors Survival benefit

Licence

CC BY + CC0

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM

DC

Additional file 4: of Patients with metastatic renal cell carcinoma who benefit from axitinib dose titration: analysis from a randomised, double-blind phase II study

Funding

Pfizer

History

Usage metrics

Categories

Keywords

Licence

Exports